Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia
Autore:
Cooper, SJ; Butler, A; Tweed, J; Welch, C; Raniwalla, J;
Indirizzi:
Queens Univ Belfast, Dept Mental Hlth, Belfast BT9 7BL, Antrim, North Ireland Queens Univ Belfast Belfast Antrim North Ireland BT9 7BL m, North Ireland Knoll Pharmaceut, Nottingham, England Knoll Pharmaceut Nottingham England oll Pharmaceut, Nottingham, England
Titolo Testata:
PSYCHOPHARMACOLOGY
fascicolo: 3, volume: 150, anno: 2000,
pagine: 237 - 243
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIPSYCHOTIC AGENTS; NEUROLEPTICS; DRUG; HALOPERIDOL; OLANZAPINE; SYMPTOMS; TRIAL;
Keywords:
schizophrenia; recurrence; clinical trial; zotepine; placebo controlled;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Cooper, SJ Queens Univ Belfast, Dept Mental Hlth, Whitla Med Bldg,97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland Queens Univ Belfast Whitla Med Bldg,97 Lisburn Rd Belfast Antrim North Ireland BT9 7BL
Citazione:
S.J. Cooper et al., "Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia", PSYCHOPHAR, 150(3), 2000, pp. 237-243

Abstract

Rationale: Zotepine is an antipsychotic drug with proven efficacy for treatment of acute episodes of schizophrenia. Antipsychotic drugs also require to be effective in prevention of recurrence. Objective: This trial was designed to compare the effects of zotepine and placebo in the prevention of recurrence of acute episodes in a population of patients with chronic schizophrenia. Methods: The study was a double-blind, parallel group, 26-week comparison of zotepine (300 mg daily, with fall back to 150 mg if necessary) versus placebo in 121 patients with chronic schizophrenia and a history of recurrence in the previous 18 months. The primary outcome measure was the time to recurrence. Other evaluations included the brief psychiatric rating scale (BPRS), the scale for the assessment of negative symptoms (SANS), the clinical global impression (CGI) severity and improvement scales, and the Simpson and Angus scale for extrapyramidal symptoms (EPS). Results: Fewer zotepine patients experienced recurrence over 26 weeks than placebo patients (4 versus 21, respectively). The estimated 26-week risk of recurrence was six times lower for zotepine than placebo (8.7% versus 52.8%; hazard ratio 0.16, 95% CI 0.053, 0.484; P<0.001). Scores on the BPRS and CGI supported theefficacy of zotepine. There was no difference between the treatments with respect to EPS. Conclusions: Zotepine is effective in preventing recurrencein patients with chronic schizophrenia. The level of EPS was not differentbetween zotepine and placebo.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:30:07